If you have been reading about heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-19. Numbers and descriptions here follow the published literature rather than marketing material.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
| Property | Value | Notes |
|---|---|---|
| Typical purity report | 95% or higher by HPLC | Area percentage at 214 nm |
| Identity confirmation | Mass spectrometry | Electrospray or MALDI |
| Powder storage | -20 C, desiccated | Protect from light |
| Solution storage | 2-8 C short term | Freeze aliquots for longer |
| Quality document | Certificate of analysis | States method and value |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
== Structure and function == GMP synthase forms a tetramer in an open box shape, which is a dimer of dimers. The R interfaces are held together with a hydrophobic core and a beta sheet, while the P dimer interfaces do not have a hydrophobic core and are more variable than the R interfaces. This enzyme also binds several ligands, including phosphate, pyrophosphate, AMP, citrate and Magnesium.
=== Lifestyle and drug management === Kalra has consistently emphasised the importance of lifestyle interventions in obesity management. He has highlighted the use of traditional and indigenous activities to improve physical function in people living with obesity. He has also worked extensively on nutrition education and research. Kalra has advocated for the recognition of "mega-nutrients" such as fibre and water, which are consumed in significantly larger quantities than macronutrients. He is also a co-author of the national consensus statement on fibre intake in India. Person-centred obesity care is another major focus of his work. His publications emphasise that obesity management requires individualised strategies rather than a uniform approach. Kalra has remained closely engaged with developments in GLP-1 receptor agonists and has published periodic updates as new evidence has emerged.
=== Computational methods in studying protein biomarkers === One example of the use of bioinformatics and the use of computational methods is the study of protein biomarkers. Computational predictive models have shown that extensive and diverse feto-maternal protein trafficking occurs during pregnancy and can be readily detected non-invasively in maternal whole blood. This computational approach circumvented a major limitation, the abundance of maternal proteins interfering with the detection of fetal proteins, to fetal proteomic analysis of maternal blood. Computational models can use fetal gene transcripts previously identified in maternal whole blood to create a comprehensive proteomic network of the term neonate. Such work shows that the fetal proteins detected in pregnant woman's blood originate from a diverse group of tissues and organs from the developing fetus. The proteomic networks contain many biomarkers that are proxies for development and illustrate the potential clinical application of this technology as a way to monitor normal and abnormal fetal development. An information-theoretic framework has also been introduced for biomarker discovery, integrating biofluid and tissue information. This new approach takes advantage of functional synergy between certain biofluids and tissues with the potential for clinically significant findings not possible if tissues and biofluids were considered individually.
Lasers can cause biological damage due to the properties of their radiation and their sometimes extremely concentrated electromagnetic power. For this reason, lasers must be labeled with standardized warnings depending on the laser class. The classification is based on the DIN standard EN 60825-1, which distinguishes between ranges of wavelengths and exposure times that lead to characteristic injuries and injury thresholds for power or energy density. The CO2-Laser was developed in 1964 by the Indian electrical engineer and physicist Chandra Kumar Naranbhai Patel (*1938) at the same time as the Nd:YAG laser (neodymium-doped yttrium aluminum garnet laser) at Bell Laboratories by LeGrand Van Uitert (1922-1999) and Joseph E. Geusic (*1931) and the Er:YAG laser (erbium-doped yttrium aluminum garnet laser) and has been used in dentistry since the early 1970s. In the hard laser field, two systems in particular are emerging for use in the oral cavity: the CO2 laser for use in soft tissue and the Er:YAG laser for use in dental hard and soft tissue. The goal of soft laser treatment is to achieve biostimulation with low energy densities. The Commission on Radiological Protection strongly recommends that the possession and purchase of class 3B and 4 laser pointers be regulated by law to prevent misuse. This is due to the increase in dangerous dazzle attacks caused by high-power laser pointers. In addition to pilots, these include truck and car drivers, train operators, soccer players, referees, and even spectators at soccer games.
Sources: en.wikipedia.org
It has been indicated that one Mn2+ ion is tightly bound to His370, while the second is loosely bound to Asp276. Human prolidase has four crystal structures, HsProl-Mn, HsProl-Na-GlyPro, HsProl-Mg-LeuPro, and HsProl-Mn-Pro. The first of these structures, HsProl-Mn, pertains to the activity of serum prolidase before binding the substrate. Furthermore, HsProl-Na-GlyPro results from substrate degradation caused by the exchange of the Mn2+ ion with Na+. This is caused by the substrate GlyPro binding to the enzyme. The third crystal structure of serum prolidase is HsProl-Mg-LeuPro. This structure functions similarly to HsProl-Na-GlyPro; however, the substrate utilized in this structure is LeuPro. Additionally, Mn2+ is replaced by Mg2+. These differences cause the structure to be more stable with a lower turnover rate. The final crystal structure of serum prolidase is HsProl-Mn-Pro, which employs Pro as the substrate. This Pro comes from the reaction being catalyzed by this enzyme. The crystal structure of prolidase is well-researched and recorded in the Protein Data Bank.
Cyprodime is a selective MOR antagonist Naltrindole is a selective DOR antagonist Norbinaltorphimine is a selective KOR antagonist J-113,397 is a selective nociceptin receptor (NOP) antagonist Other selective antagonists are also known, but the four listed above were the first selective antagonists discovered for each respective opioid receptor, and are still the most widely used. In addition to selective antagonists, AT-076 is a non-selective, balanced antagonist of all four of the opioid receptors, and was the first such agent to be discovered.
== Early life, education and career == Moroder studied chemistry at the University of Padova, where he graduated 1965 in chemistry with the doctoral thesis on synthesis of S-peptide of ribonuclease A in the laboratory of Ernesto Scoffone at the Institute of Organic Chemistry. In 1968 he joined Klaus H. Hofmann's Group at the University of Pittsburgh to work on chemical synthesis of the peptidic adrenocorticotropic hormone and its derivatives. Moroder habilitated in 1971 at the University of Padova in Chemistry of Natural Products. 1975 he became a senior research fellow in the Department of Peptide Chemistry at the Max Planck Institute for Biochemistry (MPIB) in Martinsried headed by Erich Wünsch. Between 1991 and 2008 he was the head of the Laboratory of Bioorganic chemistry at the MPIB. Since 1994 he was an adjunct professor at the Technical University of Munich.
Sources: en.wikipedia.org
Sternglass, a radiologist at the University of Pittsburgh, published several studies describing the effect of radiation from nuclear tests and the vicinity of nuclear power plants on infant mortality. In 1971, the UASEC reduced the maximum allowable radiation dose by a factor of 100. Subsequently, nuclear technology was based on the principle of "As Low As Reasonably Achievable" (ALARA). This was a coherent principle as long as it was assumed that there was no threshold and that all doses were additive. In the meantime, a transition to "As High As Reasonably Safe" (AHARS) is increasingly being discussed. For the question of evacuation after accidents, a transition to AHARS seems absolutely necessary. In both the Chernobyl and Fukushima cases, hasty, poorly organized and poorly communicated evacuations caused psychological and physical damage to those affected - including documented deaths in the case of Fukushima. By some estimates, this damage is greater than would have been expected had the evacuation not taken place. Voices such as Geraldine Thomas therefore question such evacuations in principle and call for a transition to shelter-in-place wherever possible.
==== Toll-like receptors ==== The role of toll-like receptors (TLRs) in direct recognition of peptidoglycan is controversial. In some studies, has been reported that peptidoglycan is sensed by TLR2. But this TLR2-inducing activity could be due to cell wall lipoproteins and lipoteichoic acids that commonly co-purify with peptidoglycan. Also variation in peptidoglycan structure in bacteria from species to species may contribute to the differing results on this topic.
== Structure == Osteocytes have a stellate shape, approximately 7 micrometers deep and wide by 15 micrometers in length. The cell body varies in size from 5–20 micrometers in diameter and contain 40–60 cell processes per cell, with a cell to cell distance between 20–30 micrometers. A mature osteocyte contains a single nucleus that is located toward the vascular side and has one or two nucleoli and a membrane. The cell also exhibits a reduced size endoplasmic reticulum, Golgi apparatus and mitochondria, and cell processes that radiate largely towards the bone surfaces in circumferential lamellae, or towards a haversian canal and outer cement line typical of osteons in concentric lamellar bone. Osteocytes form an extensive lacunocanalicular network within the mineralized collagen type I matrix, with cell bodies residing within lacunae, and cell/dendritic processes within channels called canaliculi.
Sources: en.wikipedia.org
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.
Dry powder is kept frozen, desiccated, and shielded from light. Dissolved material is aliquoted and frozen to limit freeze-thaw cycles. Short-term refrigerated storage is common for working solutions.
Russia registers it as a prescription nasal product. Most other markets classify it as a research chemical with no approved medical use. Oversight of purity and labeling is consequently minimal in those markets.
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.